SGLT2 Inhibitors

SGLT2 Inhibitor Use After Takotsubo Syndrome Linked to Lower Mortality

This entry was posted in Cardiovascular Diseases and tagged Mortality SGLT2 Inhibitors Takotsubo Syndrome on

Early initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors after Takotsubo syndrome was associated with significantly lower all-cause mortality in a large real-world U.S. study, although reductions in cardiovascular complications were not observed. Using the TriNetX U.S. Collaborative Network, researchers identified adults diagnosed with Takotsubo syndrome between 2015 and 2025 and compared […]

SGLT2 Inhibitors Tied to Lower Risk in Patients with Diabetes and Cirrhosis

This entry was posted in Uncategorized and tagged Cirrhosis SGLT2 Inhibitors T2D on

A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2 inhibitors offer superior multi-organ protection for the complex population of patients with both type 2 diabetes and liver cirrhosis. Among 24,259 adults (average age 64.7 years; 33.9% female) followed for a median of 2.3 years, […]